A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid) with or without Epoetin beta (NeoRecormon) in transfusion-dependent ESA-resistant patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality.

Trial Profile

A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid) with or without Epoetin beta (NeoRecormon) in transfusion-dependent ESA-resistant patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Epoetin beta
  • Indications Myelodysplastic syndromes
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 Results related to recurrent mutations in MDS patients published in the Blood.
    • 31 May 2013 Primary endpoint 'Objective-clinical-response-rate' has been met.
    • 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top